Amendments to the Claims
This listing of claims replaces all previous listings.

Claims 1 – 6 (cancelled)

Claim 7. (Currently Amended) : A method of treating osteoporosis or bone resorption in a vertebrate mammal in need thereof comprising the administering to the vertebrate mammal an effective amount of a compound of formula:



(II)

wherein Z_2 is $-O_2S-$, $-O-$, $-N(R^{107})-$, $-OS-$, or $-S-$;

w is 0, 1, 2, or 3;

R^{23} and R^{24} are the same or different and can be H or F; and

R^1 is H, ~~NH_2, NHalkylC$_1$-C$_4$, N(alkylC$_1$-C$_4$)$_2$,~~  ;

alkylC$_1$-C$_4$; OalkylC$_1$-C$_4$; SalkylC$_1$-C$_4$; alkylC$_1$-C$_4$ substituted with 1-3F, 1-2Cl, CN, or -COOalkylC$_1$-C$_4$, or cycloalkylC$_3$-C$_6$, wherein in each occurrence of the alkyl group may be straight or branched; and

R^{107} is

a) $R^{102}O-C(R^{110})(R^{111})-C(O)-$,

b) $R^{103}O-C(O)-$,

c) $R^{108}-C(O)-$,

d) $R^{109}-SO_2-$,

e) $NC-CH_2-$,

f) $FCHCH_2-$, or

g) $R^{150}R^{151}NSO_2-$;

wherein R^{102} is H, CH_3-, phenyl-CH_2-, or $CH_3C(O)$; each of R^{110} and R^{111} is selected from H or CH_3; R^{103} is alkylC$_1$-C$_3$ or phenyl; R^{108} is H, alkylC$_1$-C$_4$, aryl(CH$_2$)$_{0-5}$, $CNCH_2-$, $ClCH_2-$, Cl_2HC-, FH_2C-, F_2HC-, or cycloalkylC$_3$-C$_6$; R^{150} and R^{151} are the same or different and are selected from H, alkylC$_1$-C$_4$, or R^{150} and R^{151} taken together with the nitrogen to which each is attached forms a monocyclic heterocyclic ring having from 3 to 6 carbon atoms.

Claim 8. (Original) The method according to claim 7 wherein said mammal is a human.

Claim 9. (Original) The method according to claim 7 wherein the compound is administered in the range of about 0.1 to about 100 mg/kg of mammal body weight/day.

Claim 10. (Original) The method according the claim 7 wherein the compound is administered orally, nasally, parenterally, topically, transdermally, or rectally.

Claim 11. (currently amended) The method according to claim 7 wherein said compound is selected from the group consisting of:

~~(S) trans-[[3-[3-Fluoro-4-(tetrahydro-1-oxido-2H-thiopyran-4-yl)phenyl]-2-oxo-5-oxazolidinyl]methyl]thiourea; and~~

(S)-trans-[[3-[3-Fluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]thioacetamide, thiomorpholine S-oxide; and

pharmaceutically acceptable salts thereof.

Claim 12. (Previously Presented) The method according to claim 7 wherein said mammal is not suffering from an bacterial infection.

Claim 13. (Cancelled)